当前位置：
X-MOL 学术
›
Theranostics
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
Theranostics ( IF 12.4 ) Pub Date : 2018-03-28 , DOI: 10.7150/thno.23002 Maeva Dufies , Marie Nollet , Damien Ambrosetti , Wael Traboulsi , Julien Viotti , Delphine Borchiellini , Renaud Grépin , Julien Parola , Sandy Giuliano , Dominique Helley-Russick , Karim Bensalah , Alain Ravaud , Jean-Christophe Bernhard , Renaud Schiappa , Nathalie Bardin , Françoise Dignat-George , Nathalie Rioux-Leclercq , Stephane Oudard , Sylvie Négrier , Jean-Marc Ferrero , Emmanuel Chamorey , Marcel Blot-Chabaud , Gilles Pagès
Theranostics ( IF 12.4 ) Pub Date : 2018-03-28 , DOI: 10.7150/thno.23002 Maeva Dufies , Marie Nollet , Damien Ambrosetti , Wael Traboulsi , Julien Viotti , Delphine Borchiellini , Renaud Grépin , Julien Parola , Sandy Giuliano , Dominique Helley-Russick , Karim Bensalah , Alain Ravaud , Jean-Christophe Bernhard , Renaud Schiappa , Nathalie Bardin , Françoise Dignat-George , Nathalie Rioux-Leclercq , Stephane Oudard , Sylvie Négrier , Jean-Marc Ferrero , Emmanuel Chamorey , Marcel Blot-Chabaud , Gilles Pagès
|
The objective of the study was to use CD146 mRNA to predict the evolution of patients with non-metastatic clear cell renal cell carcinoma (M0 ccRCC) towards metastatic disease, and to use soluble CD146 (sCD146) to anticipate relapses on reference treatments by sunitinib or bevacizumab in patients with metastatic ccRCC (M1).
中文翻译：
可溶性CD146是透明细胞肾细胞癌中peistative演变和舒尼替尼疗效的预测指标
该研究的目的是使用CD146 mRNA来预测非转移性透明细胞肾细胞癌（M0 ccRCC）患者向转移性疾病的演变，并使用可溶性CD146（sCD146）来预测舒尼替尼或舒尼替尼在参考治疗中的复发贝伐单抗治疗转移性ccRCC（M1）的患者。
更新日期：2018-09-01
中文翻译：
可溶性CD146是透明细胞肾细胞癌中peistative演变和舒尼替尼疗效的预测指标
该研究的目的是使用CD146 mRNA来预测非转移性透明细胞肾细胞癌（M0 ccRCC）患者向转移性疾病的演变，并使用可溶性CD146（sCD146）来预测舒尼替尼或舒尼替尼在参考治疗中的复发贝伐单抗治疗转移性ccRCC（M1）的患者。
京公网安备 11010802027423号